- Guys, Take the Lead in Self-Checks for Testicular Cancer
- Re-focusing on Getting Fit? Heart Experts Offer These Tips
- AHA News: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
- Scientists Find Clues to Why AstraZeneca’s Vaccine May Cause Clots
- Stressed, Exhausted: Frontline Workers Faced Big Mental Strain in Pandemic
- Supply of J&J COVID Vaccine to Drop 86 Percent Next Week
- Health Highlights: April 9, 2021
- Nearly Half of U.S. Veterans Cited ‘Personal Growth’ During Pandemic: Survey
- Bright Side: Sunnier Areas Have Lower COVID-19 Death Rates
- Pandemic Has Put Many Clinical Trials on Hold
Opsumit Approved for Pulmonary Arterial Hypertension
WEDNESDAY, Oct. 23Opsumit (macitentan) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a debilitating disease characterized by high blood pressure in the lung arteries.
Pulmonary hypertension causes the heart to overwork, which can limit exercise, cause shortness of breath and create the need for a lung transplant. Opsumit relaxes the lung arteries, decreasing blood pressure in the vessels, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in clinical studies involving 742 people. The medication was found effective in “delaying disease progression,” the agency said.
The most common side effects included anemia, cold-like symptoms, bronchitis, headache, flu and urinary tract infection.
Opsumit’s label includes a boxed warning that the medication could harm a developing fetus, so the drug should not be taken by pregnant women, the FDA said.
The drug is marketed by Actelion Pharmaceuticals US, based in San Francisco.
More information
To learn more about PAH, visit the U.S. National Heart, Lung and Blood Institute.
Source: HealthDay
